Ryan C. Keefe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryan C. Keefe has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Lee
Department of Immunology, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania. 1
1 shared publication - Anna Aristarkhova
Immunobiology Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA
1 shared publication Danielle Scheffey
Adaptive Biotechnologies, Seattle, WA 98109, USA
1 shared publication- Denise Louise Faustman
Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
1 shared publication Hans F. Dias
Immunobiology Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA
1 shared publication- Hiroyuki Takahashi
Fukuoka Daigaku Chikushi Byoin
1 shared publication
Latest Publications
- Open Access
- 16 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (46) , eabq7240
BCG vaccinations drive epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes
The BCG (Bacille Calmette-Guérin) vaccine, introduced 100 years ago for tuberculosis prevention, has emerging therapeutic off-target benefits for autoimmunity. In randomized controlled trials, BCG vaccinations were shown to gradually improve two autoimmune conditions, type 1 diabetes (T1D) and multiple sclerosis. Here, we investigate the mechanisms behind the autoimmune benefits and test the hypothesis that this microbe synergy could be due to an impact on the host T cell receptor (TCR) and TCR signal strength. We show a quantitative TCR defect in T1D subjects consisting of a marked reduction in receptor density on T cells due to hypermethylation of TCR-related genes. BCG corrects this defect gradually over 3 years by demethylating hypermethylated sites on members of the TCR gene family. The TCR sequence is not modified through recombination, ruling out a qualitative defect. These findings support an underlying density defect in the TCR affecting TCR signal strength in T1D.
- 16 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (46) , eabq7240
Open AccessBCG vaccinations drive epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes
The BCG (Bacille Calmette-Guérin) vaccine, introduced 100 years ago for tuberculosis prevention, has emerging therapeutic off-target benefits for autoimmunity. In randomized controlled trials, BCG vaccinations were shown to gradually improve two autoimmune conditions, type 1 diabetes (T1D) and multiple sclerosis. Here, we investigate the mechanisms behind the autoimmune benefits and test the hypothesis that this microbe synergy could be due to an impact on the host T cell receptor (TCR) and TCR signal strength. We show a quantitative TCR defect in T1D subjects consisting of a marked reduction in receptor density on T cells due to hypermethylation of TCR-related genes. BCG corrects this defect gradually over 3 years by demethylating hypermethylated sites on members of the TCR gene family. The TCR sequence is not modified through recombination, ruling out a qualitative defect. These findings support an underlying density defect in the TCR affecting TCR signal strength in T1D.